Springer Nature

Why did different sexes evolve? It’s a question as old as biology, but Prof. Dr Elvira Hörandl (University of Göttingen), with the help of biochemist Dr Franz Hadacek, may have discovered an important piece of the answer.

Associated article: Oxygen, life forms, and the evolution of sexes in multicellular eukaryotes

https://www.nature.com/articles/s41437-020-0317-9

In a bumper episode, filled with editorial expertise and top writing tips, discover why you should publish in Heredity in 2021!

Join host James Burgon as he shares his highlights from the past year of the Heredity Podcast.

Interest is growing in the use of the psychedelic drug LSD for psychiatric research and even potentially for treatment. But placebo-controlled studies conducted to date have used just one dose of the drug—none have investigated the impacts of a variety of dosages within the same subjects. In addition, past studies did not use pharmaceutically-defined dosages of LSD, which has made verifying the effects of a particular dose difficult. To address this gap, Matthias Liechti, professor in the department of clinical pharmacology and toxicology at the University of Basel in Switzerland, and his colleagues conducted a study. Have a listen to learn more!

Related article: https://www.nature.com/articles/s41386-020-00883-6

Pediatric chronic kidney disease (pCKD) results in a life-long burden that requires routine care. Neurocognitive dysfunction, specifically impairment on tasks of executive function, is a well-established comorbidity but there is a paucity of data exploring the neurobiology of these cognitive deficits. In this episode, we meet early career investigator, Dr Lyndsay Harshman, a pediatric nephrologist at the University of Iowa's Stead Family Children's hospital, who compared the brain morphometry between early stage pCKD children and their typically developing peers, and linked this brain morphometry with disease status and performance on neurocognitive assessments.

Related article: https://www.nature.com/articles/s41390-020-01203-w

While newborn screening is gradually expanding in many states in the U.S. and other countries to include some members of a class of diseases known as lysosomal storage diseases (LSD), there has yet to be a screening test available for one LSD called metachromatic leukodystrophy (MLD). MLD is a rare neurogenetic condition that is often fatal and there is currently no widely available approved treatment. However, there are a number of promising therapies under development in ongoing clinical trials. Michael H. Gelb, PhD, professor of chemistry and biochemistry at the University of Washington, recently turned his attention to developing a newborn screening test for MLD, which he discusses on this month’s GenePod. Based on the results of more than 27,000 newborns screened for this study, Dr. Gelb believes that a newborn screening test for MLD, upon completion of a second unblinded prospective study, could soon become part of the Federal Recommended Uniform Screening Panel. Tune in!

Related Article - https://www.nature.com/articles/s41436-020-01017-5

Therapeutic Hypothermia has long been the standard of care for infants with moderate to severe neonatal encephalopathy. However, the future of treatment for neonatal encephalopathy (NE) will focus on hypothermia adjuvant therapies. There needs to be a rethink in how future NE clinical trials are designed and analyzed, according to a multi-disciplinary expert panel who met at the 'Hypoxic-Ischemic Encephalopathy Symposium: Developing the Future'. In this episode we meet Dr. Kristen Benninger, a neonatologist at Nationwide Children's Hospital in Columbus Ohio who wrote up the panel's summary. Have a listen! Related Article: https://www.nature.com/articles/s41390-020-0859-9

Pediatric Pulmonary Hypertension (PAH) is a heterogeneous disease, characterised by sustained elevation of pulmonary arterial pressures and death from right ventricular failure. Given the extremely high burden of morbidity and mortality associated with this disease, and the risk of the invasive procedures required for diagnostics, novel biomarkers for this disease would be beneficial. In this episode, we meet Early Career Investigator, Dr. Megan Griffiths from Johns Hopkins University, School of Medicine, who examined two candidate IGF axis proteins as potential predictors of PAH severity. Have a listen!

Related article: https://www.nature.com/articles/s41390-020-01113-x

Effective decision making in the Pediatric Intensive Care Unit relies on quickly ascertaining diagnostic information in order to deliver a tailored clinical response. The utility of rapid genetic testing of critically ill patients has been demonstrated several times, owing to their relatively high diagnostic yield. However the cost and slow turnaround of results have been major barriers in the past to the widespread uptake of this technology in the clinical setting. In this episode, we meet Professor Steve Kernie from Columbia University Irving Medical Center and Morgan Stanley Children's hospital, who conducted a pilot study to assess what impact the use of rapid exome sequencing would have on the length of stay of a subset of children admitted to the Pediatric Intensive Care Unit. Have a listen!

Related article: https://www.nature.com/articles/s41390-020-0858-x

Dr. Peter Sadow , Director of Head and Neck Pathology at MGH discusses with Modern Pathology Editor Dr. George Netto his recent work defining morphologic correlates of the expanding list of Kinase Fusions driving thyroid cancers. A triage testing algorithm and therapeutic implications are highlighted in the discussion. Study by Chu et al, Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.

Associated article: Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization - https://www.nature.com/articles/s41379-020-0638-5